{"commentary":{"count":5,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":3,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"SURVIVE HERoes","nct_id":"NCT06643585","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=survive-heroes-nct06643585. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"SURVIVE HERoes","arms":[{"description":"Trastuzumab-Deruxtecan (i.v. 5,4 mg/kg, q3w) + endocrine therapy (if hormonal-receptor-positive) for 16 cycles or until relapse, if earlier","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Continuous treatment of physician's choice (may include endocrine treatment, CDK4/6-Inhibition, T-DM1, Olaparib, Trastuzumab, Pertuzumab, Capecitabine or Neratinib)","label":"Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-04-22","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":180,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Trastuzumab-Deruxtecan","type":"DRUG"},{"name":"Physicians Choice (PhC).","type":"OTHER"}],"last_update":"2025-05-02","lead_sponsor":"Prof. Wolfgang Janni","official_title":"SURVIVE HERoes - A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-04-22","type":"ESTIMATED"},"primary_outcomes":[{"measure":"ctDNA clearance rate 12 months after randomization","timeFrame":"from enrollment to end of treatment after 12 months"}],"references":[],"start_date":{"date":"2025-04-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse","url":"https://clinicaltrials.gov/study/NCT06643585"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/survive-heroes-nct06643585"}